Bioabsorbable Scaffolds - APAC Analysis and Market Forecasts

Introduction

Bioabsorbable Scaffolds - APAC Analysis and Market Forecasts

Summary

Coronary artery disease (CAD) and peripheral artery disease (PAD) are global public health and socioeconomic issues that affect millions of lives each year. Bioabsorbable scaffolds (BAS), which provide transient support to the vessel, are viable alternatives to permanent drug-eluting stents (DES) and bare metal stents (BMS) implants. In the report, BAS are defined as fully-bioabsorbable devices that are used in stenting procedures that completely disappear from the target vessel overtime. Stents such as BioMatrix Flex by Biosensors International and Synergy by Boston Scientific Corporation are not included in the report because they are metallic DES with bioabsorbable polymer coatings. Absorption of the bioabsorbable polymer coating still leaves behind a permanent BMS inside the vessel.

This report focuses on the current and future APAC (Japan, China and India). This report identifies the unmet needs in the market, provides an understanding of physician perception of BAS, and evaluates the adoption of BAS in the future. Through GlobalData’s analysis, it is evident that although there will be early adopters within the APAC region and the widespread adoption of BAS will begin slowly. Large-scale, long-term studies need to be conducted to demonstrate their clinical efficacy, and new stent technologies need to be integrated appropriately into the existing reimbursement systems throughout the APAC region covered in this report. To successfully market BAS, companies need to design novel scaffold platforms that address the current unmet needs of conventional drug-eluting and BMS, and show superior clinical performance to the stents that are currently marketed and being used in modern clinics.

*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.

Highlights

Key Questions Answered

- What is the current and future market outlook for Bioabsorbable Scaffolds in the APAC region? What trends are affecting the Bioabsorbable Scaffold market?

- What are the market sizes of each bioabsorbable scaffold segment?

- What clinical factors and technical specifications will influence a physician to use bioabsorbable scaffolds over conventional DES and BMS stents?

- What are unmet needs in the bioabsorbable scaffold market? What are the clinical and non-clinical barriers in this space?

Reasons to buy

- “What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading physicians and other stakeholders from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents
for Bioabsorbable Scaffolds - APAC Analysis and Market Forecasts

• 1 Table of Contents

  1.1 List of Tables

  1.2 List of Figures

  2 Executive Summary

  2.1 Key Metrics in the 10 Major Markets

  2.2 Technological Trends

  2.3 Key Players in the Bioabsorbable Scaffold Market

  2.4 Bioabsorbable Scaffold Market Outlook

  2.5 What Do Physicians Think?

  3 Introduction

  3.1 Catalyst

  3.2 Related Reports

  4 Disease Overview

  4.1 Coronary Artery Disease

  4.2 Peripheral Artery Disease

  4.3 Anatomy and Physiology

  4.4 Pathophysiology

  4.4.1 Coronary Artery Disease

  4.4.2 Peripheral Artery Disease

  4.5 Clinical Presentation

  4.5.1 Symptoms of Coronary Artery Disease

  4.5.2 Symptoms of Peripheral Artery Disease

  4.6 Risk Factors

  4.6.1 Coronary Artery Disease

  4.6.2 Peripheral Artery Disease

  4.7 Disease Segments

  4.7.1 Coronary Artery Disease

  4.7.2 Peripheral Artery Disease

  4.8 Diagnosis

  4.8.1 Coronary Artery Disease

  4.8.2 Peripheral Artery Disease

  4.9 Clinical Outcomes

  4.9.1 Treatment Paradigm

  4.9.2 Treatment Modalities

  4.9.3 Coronary/Peripheral Artery Bypass Grafting

  4.9.4 Interventional Cardiology

  5 Competitive Assessment

  5.1 Overview

  5.2 Absorb BVS - Abbott Vascular

  5.2.1 Efficacy

  5.3 Remedy - Kyoto Medical Planning

  5.3.1 Efficacy

  5.4 DESolve - Elixir Medical Corperation

  5.4.1 Efficacy

  5.5 Pure - Arterial Remodeling Technologies

  5.5.1 Efficacy

  6 Unmet Needs

  6.1 Develop a Fully-Bioabsorbable Stent

  6.2 Reduce the Risk of Complications

  6.3 Reduce the Need for Stent-in-Stent Procedures

  6.4 Long-Term Clinical Data

  6.5 Reduce the Rate of Stent Fracture

  6.6 Dual Anti-Platelet Therapy

  6.7 Imaging

  7 Pipeline Products

  7.1 Overview

  7.2 Coronary Artery Disease - Pipeline Products

  7.2.1 Overview

  7.2.2 Polymer-Based Bioabsorbable Scaffolds

  7.2.3 Metallic Bioabsorbable Scaffolds

  7.2.4 Summary

  7.3 Peripheral Artery Disease - Peripheral Bioabsorbable Scaffold Product Pipeline

  7.3.1 Overview

  7.3.2 Summary

  8 Industry Overview

  8.1 Procedure Trends

  8.1.1 Coronary Artery Disease

  8.1.2 Peripheral Artery Disease

  9 Market Access

  9.1 Overview

  9.2 Regulatory Process

  9.2.1 Asia-Pacific

  9.3 Physician Decision-Making Process

  9.4 Role of Group Purchasing Organizations

  9.5 Lack of Clinical Data

  9.6 Regional-Level Control

  9.7 Cost Considerations

  9.7.1 Asia-Pacific

  9.8 Reimbursement Trends

  9.8.1 Asia-Pacific

  9.9 Regulatory Issues/Recalls

  9.10 Product Recalls

  10 Mergers and Acquisitions

  10.1 ART and Terumo Corparation

  10.2 Xenogenics Corporation and Multicell Technologies

  10.3 Icon Interventional Systems and Ariad Pharmaceuticals

  10.4 Boston Scientific Corporation

  11 Current and Future Players

  11.1 Overview

  11.2 Trends in Corporate Strategy

  11.3 Company Profiles

  11.3.1 Abbott Vascular

  11.3.2 Kyoto Medical Planning Co., Ltd.

  11.3.3 Arterial Remodeling Technologies

  11.3.4 Elixir Medical Corporation

  11.3.5 Cardionovum

  11.3.6 Reva Medical

  11.3.7 OrbusNeich Medical

  11.3.8 Amaranth Medical

  11.3.9 Biotronik

  11.3.10 Lepu Medical Technology

  11.3.11 HuaAn Biotechnology Co., Ltd.

  11.3.12 Lifetech Scientific (Shenzhen) Co., LTD. (Lifetech Shenzhen)

  11.3.13 Arterius

  11.3.14 S3V Vascular Technologies

  11.3.15 Tepha Inc.

  11.3.16 Zorion Medical

  11.3.17 Xenogenics Corporation

  11.3.18 Meril Life Sciences

  11.3.19 Boston Scientific Corporation

  11.3.20 Icon Interventional Systems

  12 Market Drivers, Opportunities and Barriers

  12.1 Market Drivers

  12.1.1 Rising Prevalence of Disease

  12.1.2 Avoid Stent-in-Stent Procedures

  12.1.3 Reduce/Eliminate Dual Anti-Platelet Therapy

  12.1.4 Availability of Long-Term Data

  12.1.5 Treatment Considerations

  12.1.6 Accurate Stent Placement

  12.2 Opportunities

  12.2.1 BAS Segmentation

  12.2.2 Expanding the Indications for BAS

  12.2.3 Target High-Risk Patients

  12.2.4 Improve Deliverability of BAS

  12.2.5 Emerging Markets

  12.3 Market Barriers

  12.3.1 Slow Adoption

  12.3.2 Complications Associated with BAS

  12.3.3 High Average Selling Price

  12.3.4 Reimbursement

  12.3.5 Substitutes

  13 Market Outlook and Forecast

  13.1 Japan

  13.1.1 Overview

  13.1.2 Market Analysis

  13.2 China

  13.2.1 Overview

  13.2.2 Market Analysis

  13.3 India

  13.3.1 Overview

  13.3.2 Market Analysis

  14 Appendix

  14.1 Bibliography

  14.2 Abbreviations

  14.3 Report Methodology

  14.3.1 Overview

  14.3.2 Coverage

  14.3.3 Primary Research -Key Opinion Leader Interviews

  14.3.4 Primary Research Interviews - Physician and Industry Participants

  14.3.5 Physician Survey

  14.3.6 Expert Panel Validation

  14.3.7 Secondary Research

  14.4 Forecasting Methodology

  14.5 Physicians and Specialists Included in This Study

  14.6 About the Authors

  14.6.1 Analysts

  14.6.2 James Coutcher, Global Head of Healthcare

  14.7 About GlobalData

  14.8 Contact Us

  14.9 Disclaimer

List Of Tables
in Bioabsorbable Scaffolds - APAC Analysis and Market Forecasts

1.1 List of Tables

Table 1: Bioabsorbable Scaffolds, Key Metrics in the 10MM, 2014-2021

Table 2: Symptoms of CAD

Table 3: Symptoms of PAD

Table 4: Risk Factors Associated With CAD

Table 5: Risk Factors Associated With PAD

Table 6: Disease Segments for CAD

Table 7: Disease Segments for PAD

Table 8: Methods for Diagnosing CAD

Table 9: Methods for Diagnosing PAD

Table 10: Types of CABG

Table 11: Drugs Incorporated Into DES

Table 12: Marketed BAS Products

Table 13: Absorb BVS Product Profile

Table 14: Absorb BVS Clinical Trials

Table 15: Absorb BVS SWOT Analysis, 2015

Table 16: Remedy Product Profile

Table 17: Remedy SWOT Analysis, 2015

Table 18: DESolve Product Profile

Table 19: DESolve Clinical Trials

Table 20: DESolve SWOT Analysis, 2015

Table 21: Pure Product Profile

Table 22: Pure SWOT Analysis, 2015

Table 23: Coronary BAS Product Pipeline, 2015

Table 24: Igaki-Tamai Stent SWOT Analysis, 2015

Table 25: Fantom Scaffold SWOT Analysis, 2015

Table 26: ART18Z Scaffold SWOT Analysis, 2015

Table 27: Fortitude Scaffold SWOT Analysis, 2015

Table 28: ArterioSorb Scaffold SWOT Analysis, 2015

Table 29: Xinsorb Scaffold SWOT Analysis, 2015

Table 30: Ideal BioStent SWOT Analysis, 2015

Table 31: DREAMS Scaffold SWOT Analysis, 2015

Table 32: Peripheral BAS Product Pipeline, 2015

Table 33: Magic Explorer Scaffold SWOT Analysis, 2015

Table 34: ESPRIT BVS Stent SWOT Analysis, 2015

Table 35: GPOs in the US and EU

Table 36: Abbott Vascular Company Profile

Table 37: Marketed BAS Products by Abbott Vascular

Table 38: Pipeline BAS Products by Abbott Vascular

Table 39: Abbott Vascular SWOT Analysis, 2015

Table 40: Kyoto Medical Planning Company Profile

Table 41: Marketed BAS Products by Kyoto Medical Planning

Table 42: Pipeline BAS Products by Kyoto Medical Planning

Table 43: Kyoto Medical Planning SWOT Analysis, 2015

Table 44: ART Company Profile

Table 45: Marketed BAS Products by ART

Table 46: ART’s BAS Pipeline Products

Table 47: ART SWOT Analysis, 2015

Table 48: Elixir Medical Corporation Company Profile

Table 49: Marketed BAS Products by Elixir Medical

Table 50: Elixir Medical Corporation SWOT Analysis, 2015

Table 51: Cardionovum Company Profile

Table 52: Cardionovum’s BAS Pipeline Products

Table 53: Cardionovum SWOT Analysis, 2015

Table 54: REVA Medical’s BAS Pipeline Products

Table 55: REVA Medical SWOT Analysis, 2015

Table 56: OrbusNeich Medical Company Profile

Table 57: OrbusNeich Medical’s BAS Pipeline Products

Table 58: OrbusNeich Medical SWOT Analysis, 2015

Table 59: Amaranth Medical Company Profile

Table 60: Amaranth Medical’s BAS Pipeline Products

Table 61: Amaranth Medical SWOT Analysis, 2014

Table 62: Biotronik Company Profile

Table 63: Biotronik’s BAS Pipeline Products

Table 64: Biotronik SWOT Analysis, 2015

Table 65: Lepu Medical Technology Company Profile

Table 66: Lepu Medical Technology’s BAS Pipeline Products

Table 67: Lepu Medical Technology SWOT Analysis, 2015

Table 68: HuaAn Biotechnology Co., Ltd. Company Profile

Table 69: HuaAn Biomedical Co., Ltd.’s BAS Pipeline Products

Table 70: HuaAn Biomedical Co., Ltd. SWOT Analysis, 2015

Table 71: Lifetech Scientific Co., LTD Company Profile

Table 72: Lifetech Scientific’s BAS Pipeline Products

Table 73: Lifetech Scientific SWOT Analysis, 2015

Table 74: Arterius Company Profile

Table 75: Arterius BAS Pipeline Products

Table 76: Arterius SWOT Analysis, 2015

Table 77: S3V Vascular Technologies Company Profile

Table 78: S3V Vascular Technologies’ BAS Pipeline Product

Table 79: S3V Vascular Technologies SWOT Analysis, 2015

Table 80: Tepha Inc. Company Profile

Table 81: Tepha Inc.’s BAS Pipeline Product

Table 82: Tepha Inc. SWOT Analysis, 2015

Table 83: Zorion Medical Company Profile

Table 84: Zorion Medical’s BAS Pipeline Product

Table 85: Zorion Medical SWOT Analysis, 2015

Table 86: Xenogenics Corporation Company Profile

Table 87: Xenogenics Corporation’s BAS Pipeline Product

Table 88: Xenogenics Corporation SWOT Analysis, 2015

Table 89: Meril Life Sciences Company Profile

Table 90: Meril Life Science’s BAS Pipeline Product

Table 91: Meril Life Sciences SWOT Analysis, 2015

Table 92: Boston Scientific Corporation Company Profile

Table 93: Boston Scientific Corporation SWOT Analysis, 2015

Table 94: Icon Interventional Systems Company Profile

Table 95: Japan BAS Market Revenue ($m), 2012-2021

Table 96: China BAS Market Revenue ($m), 2012-2021

Table 97: India BAS Market Revenue ($m), 2012-2021

Table 98: Primary Research Interviews Completed

Table 99: Physicians Surveyed, By Country

List Of Figures, Charts and Diagrams
in Bioabsorbable Scaffolds - APAC Analysis and Market Forecasts

1.2 List of Figures

Figure 1: BAS Global Market Share Comparison By Major Market, 2014 and 2021

Figure 2: Anatomy of the Human Heart

Figure 3: Pathophysiology of CAD

Figure 4: Pathophysiology of PAD

Figure 5: Treatment Modalities - CAD

Figure 6: Treatment Modalities - PAD

Figure 7: Types of Stents Used to Treat CAD and PAD

Figure 8: APAC Procedure Volume of Stents Used in Coronary Interventions, 2012-2021

Figure 9: APAC Peripheral Stenting Procedure Volume, by Artery, 2012-2021

Figure 10: Japan BAS Market Revenue ($m), 2012-2021

Figure 11: China BAS Market Revenue ($m), 2012-2021

Figure 12: India BAS Market Revenue ($m), 2012-2021

Additional Details

Publisher

Global Data

Publisher Information

Reference

27809 | GDME1156CFR

Report Format

PDF

Related Reports